Vancouver, British Columbia--(Newsfile Corp. - January 31, 2019) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQX: ICOTF) ("iCo" or "the Company") is pleased to announce that it has issued a total of 3,000,000 units (the "Units") pursuant to the first tranche of a non-brokered private placement (the "Private Placement"). The Company plans to issue up to 15,000,000 Units at a price of $0.05 per Unit for total gross proceeds of $750,000 pursuant to the Private Placement. Each Unit will consist of one...
DGAP-News: iCo Therapeutics Inc. / Key word(s): Miscellaneous iCo Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Update 29.11.2018 / 23:00 The issuer is solely responsible for the content of this announcement. Vancouver, British Columbia--(Newsfile Corp. - November 29, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ('iCo' or the 'Company'), today reported financial results for the quarter and nine months ended September 30, 2018. Amounts, unless specified...
Vancouver, British Columbia--(Newsfile Corp. - November 29, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the quarter and nine months ended September 30, 2018. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS"). Stated Andrew Rae, President and CEO of iCo Therapeutics Inc., "This quarter was a period of significant achievement for iCo...
DGAP-News: iCo Therapeutics Inc. / Key word(s): Miscellaneous iCo Therapeutics Provides Corporate Update, Including Drug Supply for Next Oral Amphotericin B Efficacy Study 15.11.2018 / 14:01 The issuer is solely responsible for the content of this announcement. Vancouver, British Columbia--(Newsfile Corp. - November 15, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ('iCo' or the 'Company'), today announced several positive corporate developments and updated guidance on milestones for two...
Vancouver, British Columbia--(Newsfile Corp. - November 15, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today announced several positive corporate developments and updated guidance on milestones for two drug candidates. -iCo Therapeutics announces that it now has sufficient drug supply for a proposed mid-staged clinical trial, which may be as large as 90 patients in size, investigating the efficacy and safety study of its oral Amphotericin B (oral Amp B)...
DGAP-News: iCo Therapeutics Inc. / Key word(s): Miscellaneous iCo Therapeutics Announces Oral Amphotericin B Clinical Advisory Board 23.10.2018 / 14:00 The issuer is solely responsible for the content of this announcement. Vancouver, British Columbia--(Newsfile Corp. - October 23, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ('iCo' or the 'Company'), today announced the formation of an oral Amphotericin B clinical advisory board with the appointment of Dr. John Perfect and Dr. David...
Vancouver, British Columbia--(Newsfile Corp. - October 23, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today announced the formation of an oral Amphotericin B clinical advisory board with the appointment of Dr. John Perfect and Dr. David Denning. Stated Dr. Peter Hnik, Chief Medical Officer, "we look forward to working with our clinical advisors as we refine the design of mid staged clinical studies for our oral Amphotericin B candidate. We are fortunate to have...
Vancouver, British Columbia--(Newsfile Corp. - October 2, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today announced several positive corporate developments and updated guidance on milestones for two drug candidates. iCo Therapeutics Australia Pty Ltd. has received full payment of approximately $462,000 Australian dollars (AUD) for R&D expenditures conducted during its past fiscal year, during which the Company conducted a Phase 1 clinical study. Refundable...
DGAP-News: iCo Therapeutics Inc. / Key word(s): Miscellaneous iCo Therapeutics Provides Corporate Update 02.10.2018 / 14:00 The issuer is solely responsible for the content of this announcement. Vancouver, British Columbia--(Newsfile Corp. - October 2, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ('iCo' or the 'Company'), today announced several positive corporate developments and updated guidance on milestones for two drug candidates. iCo Therapeutics Australia Pty Ltd. has received full...
Vancouver, British Columbia--(Newsfile Corp. - September 6, 2018) - iCo Therapeutics ("iCo" or the "Company") (TSXV: ICO) (OTCQB: ICOTF), today announced additional positive pharmacokinetic data from its recent Phase 1 study of its Oral Amphotericin B (Oral Amp B) candidate. Previously the Company reported that Oral Amp B achieved a median Cmax of 28 ng/mL and AUC0-inf of 1030 hr*ng/mL at the lowest dose of Oral Amphotericin B of 100 mg, demonstrating superiority of area under the concentration...
DGAP-News: iCo Therapeutics Inc. / Key word(s): Miscellaneous iCo Therapeutics Announces Additional Positive Pharmacokinetic Results and Presentation at Global Investment Conference 06.09.2018 / 14:00 The issuer is solely responsible for the content of this announcement. Vancouver, British Columbia--(Newsfile Corp. - September 6, 2018) - iCo Therapeutics ('iCo' or the 'Company') (TSXV: ICO) (OTCQB: ICOTF), today announced additional positive pharmacokinetic data from its recent Phase 1 study of...
Vancouver, British Columbia--(Newsfile Corp. - August 29, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the quarter and six months ended June 30, 2018. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS"). Stated Andrew Rae, President and CEO of iCo Therapeutics Inc., "the quarter represented a period of significant achievement for iCo...
DGAP-News: iCo Therapeutics Inc. / Key word(s): Miscellaneous iCo Therapeutics Announces Second Quarter 2018 Financial Results And Corporate Update 30.08.2018 / 00:32 The issuer is solely responsible for the content of this announcement. Vancouver, British Columbia--(Newsfile Corp. - August 29, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ('iCo' or the 'Company'), today reported financial results for the quarter and six months ended June 30, 2018. Amounts, unless specified otherwise, are...
Vancouver, British Columbia--(Newsfile Corp. - July 16, 2018) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), and its subsidiary iCo Therapeutics Australia Pty Ltd., today announced a positive pharmacokinetic secondary end point in its Phase 1 clinical study. Previously the Company reported that the study met its primary endpoint of safety and tolerability of iCo-019 (Oral Amp B) following oral administration of single ascending doses (4 dose levels) in healthy...
DGAP-News: iCo Therapeutics Inc. / Key word(s): Miscellaneous iCo Therapeutics Announces Positive Secondary Endpoint and Advancement into Later Stage Clinical Trials - Phase 1 Oral Amphotericin B 16.07.2018 / 14:01 The issuer is solely responsible for the content of this announcement. Vancouver, British Columbia--(Newsfile Corp. - July 16, 2018) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ('iCo' or 'the Company'), and its subsidiary iCo Therapeutics Australia Pty Ltd., today announced a...
Vancouver, British Columbia--(Newsfile Corp. - June 27, 2018) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), and its subsidiary iCo Therapeutics Australia Pty Ltd., today announced a positive primary end point in its Phase 1 clinical study. The study met its primary endpoint of safety and tolerability of iCo-019 (Oral Amp B) following oral administration of single ascending doses (4 dose levels) in healthy subjects. There were no serious adverse events (SAEs) and no...
DGAP-News: iCo Therapeutics Inc. / Key word(s): Miscellaneous iCo Therapeutics Announces Positive Clinical Outcome - Primary Endpoint Met in Phase 1 Oral Amphotericin B Study 27.06.2018 / 14:00 The issuer is solely responsible for the content of this announcement. Vancouver, British Columbia--(Newsfile Corp. - June 27, 2018) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ('iCo' or 'the Company'), and its subsidiary iCo Therapeutics Australia Pty Ltd., today announced a positive primary end...
Vancouver, British Columbia--(Newsfile Corp. - June 20, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today announced the completion of recruitment of all 32 subjects in the Company's Phase 1 Oral Amphotericin B (Oral Amp B) study. Phase 1 Oral Amp B Clinical Trial The Phase 1 Australian study is a randomized, double-masked, placebo-controlled, single dose ascending study to assess the safety, tolerability, and bioavailability of iCo-019 (Oral Amphotericin B)....
DGAP-News: iCo Therapeutics Inc. / Key word(s): Miscellaneous iCo Therapeutics Provides Corporate Update, Announces Completion of Phase 1 Recruitment 20.06.2018 / 14:00 The issuer is solely responsible for the content of this announcement. Vancouver, British Columbia--(Newsfile Corp. - June 20, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ('iCo' or 'the Company'), today announced the completion of recruitment of all 32 subjects in the Company's Phase 1 Oral Amphotericin B (Oral Amp B)...
Vancouver, British Columbia--(Newsfile Corp. - May 30, 2018) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today reported financial results for the quarter ended March 31, 2018. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS"). "Recently, we dosed our first subject with our novel Oral Amphotericin B (Oral AmpB) formulation. Strong recruitment has resulted in our dosing of all...